Serum Visfatin Levels in Pregnant Women with Gestational Diabetes Mellitus


  • Author- Samita Yasmin,1 Sana Rasheed Chaudhry,2 Muniza Saeed,3 Komal Iqbal,4 Isma Meer5


The clinical data linking circulating visfatin to the parameters of glucose metabolism and insulin resistance during gestational diabetes mellitus (GDM) pregnancy is widely contentious. Aim of this study is to explore the changes in maternal serum visfatin levels in normal and pregnancy complicated with gestational diabetes mellitus (GDM).


This study was carried out in Lahore General Hospital /PGMI. Forty two pregnant females in the age range 25-35 years, at 32-36 weeks of gestation was included in this study and divided into two groups. Group1 includes 21 normal healthy pregnant females as control and Group II includes diagnosed cases of GDM. Fasting blood samples were drawn during 32-36 weeks of gestation for serum visfatin, fasting insulin and fasting blood sugar. Serum visfatin levels were determined by visfatin/Nampt/PBEF human ELISA kit manufactured by Glory science company, USA. Serum Insulin was determined by using Insulin ELISA Kit manufactured by Calbiotech company, USA. Serum glucose was determined by chemistry analyzer Micro lab 300. Homeostasis Model Assessment (HOMA)-IR was used as an insulin resistance index which was obtained by the product of fasting blood glucose and fasting levels of insulin and dividing it by 22.5. The data was entered and analyzed by using SPSS-23. Mean + SD was calculated for quantitative variables. Independent sample and paired t-test were applied and statistical significance was considered with a p<0.05.


 Levels of serum Vistafin were compared amongst group I and group II during third trimester revealed a statistically significant difference (p=0.00).


 Visfatin has been suggested to have a role in pathogenesis of GDM as it appears to be considered in regulation of glucose metabolism and insulin resistance.


Visfatin Level, Gestational Diabetes Mellitus, Homeostasis Model Assessment.